Industry News
Biotechnology Industry News
The FDA is freeing Intellia’s…
The FDA is freeing Intellia’s CRISPR therapy from one of two clinical holds, allowing a phase 3 study to resume after a grade 4 liver event and subsequent patient death was reported in the sister
Ahead of its acquisition by cancer…
Ahead of its acquisition by cancer imaging company Kuva Labs, Lisata Therapeutics has regained the Chinese rights to its lead solid tumor candidate from Qilu Pharmaceutical.
Four years after listing on the…
Four years after listing on the Nasdaq, Genenta Sciences is taking the business in an unexpected direction.
Boehringer Ingelheim has penned a…
Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody.
Roche’s dual GLP-1/GIP receptor…
Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s decision to move the asset into phase 3 studies in the coming weeks.
Qilu Pharmaceutical has struck a…
Qilu Pharmaceutical has struck a deal to tap into Insilico Medicine’s artificial intelligence drug development capabilities, offering up to $120 million to collaborate on small molecules for treating cardiometabolic diseases.
European investment firm Gimv will…
European investment firm Gimv will no longer put funds into the life sciences sector, choosing instead to focus on its long-term investments and finding new value in four other key areas.
While 2025 was dedicated to…
While 2025 was dedicated to “understanding a little bit more about the rules of this game that we’re playing,” 2026 is all about being active players in the game, McKinsey senior partner Greg Graves said
What do you get when you insert a…
What do you get when you insert a molecular glue degrader into an antibody-drug conjugate? Fortitude Biomedicines is in the process of finding out.
Former CytoDyn CEO Nader…
Former CytoDyn CEO Nader Pourhassan, Ph.D., has received a 30-month prison sentence, or two and a half years, after being convicted on charges related to defrauding biotech investors.
AstraZeneca is showing no signs of…
AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its hometown, despite keeping its options open.
As the Trump administration erodes…
As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.
Despite remaining a fertile…
Despite remaining a fertile hunting ground for Big Pharmas to snap up biotechs or license new therapies, the U.K. hasn’t produced any new publicly listed drug developers of its own for many years.
Sanofi has reported mixed phase 3…
Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospects of a molecule tipped to generate blockbuster sales.
Bristol Myers Squibb added a big…
Bristol Myers Squibb added a big name to its executive roster with the appointment of Harald Hampel, M.D., Ph.D. as its new SVP and worldwide head of medical affairs, neuroscience. Hampel comes to BMS after
Hoth Therapeutics has shared phase…
Hoth Therapeutics has shared phase 2 results on its treatment of EGFR inhibitor-induced skin toxicities, ticking off another milestone for a candidate designed to complement cancer therapies.
In a reminder of the money still…
In a reminder of the money still available for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in series D funds to bankroll phase 2 studies of its oral GLP-1 receptor agonist.
Corcept Therapeutics’…
Corcept Therapeutics’ relacorilant has improved overall survival in a phase 3 ovarian cancer study, building on interim data published last year to give the biotech momentum heading into an FDA approval ruling.
Bristol Myers Squibb will pay…
Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic.
After a short delay and concerns…
After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease and complete response to support